Seegene Unveils CURECA™: A Revolutionary Automated PCR Testing Solution

In a pioneering leap forward in molecular diagnostics, Seegene Inc. has announced the development of CURECA™, a fully automated system designed for next-generation PCR testing. This innovative solution was showcased at the ESCMID Global 2025 conference, highlighting its potential to transform laboratory operations and set new standards in diagnostic efficiency.

A Game Changer in Diagnostics

CURECA™, an abbreviation for Continuous Unlimited Random Access Expandable and Customizable full Automation, is a cutting-edge system aimed at replacing the need for manual intervention throughout the PCR testing process. From sample pre-processing to the analysis of results, CURECA™ operates seamlessly, offering round-the-clock testing capabilities without requiring specialized personnel. This automation is set to redefine the expectations for laboratory efficiency and accuracy in diagnostic testing.

During the ESCMID conference held in Vienna, Austria, from April 11 to 15, 2025, Seegene presented a conceptual video illustrating the potential workflows enabled by CURECA™. The anticipated hands-on demonstration of the system is scheduled for July 2025 at the Association for Diagnostics Laboratory Medicine (ADLM) conference in Chicago, furthering excitement and anticipation in the MDx community.

Streamlining PCR Processes

PCR testing has been a cornerstone of diagnostics, especially during the COVID-19 pandemic. CURECA™ integrates two primary components: the Customizable Pre-processing System (CPS) for sample handling and the Customizable and Expandable Full Automation (CEFA) for the comprehensive automation of the PCR process, including nucleic acid extraction, PCR setup, gene amplification, and result analysis.

The CPS is designed to handle various sample types such as blood, urine, and others while optimizing steps like sorting, centrifugation, and mixing. Traditionally, these processes relied heavily on skilled laboratory workers, making them labor-intensive and prone to human error. With CURECA™, Seegene aims to minimize these risks, allowing laboratories to focus on critical tasks while maintaining high standards of quality control.

Modular Design for Flexibility

One of the standout features of CURECA™ is its modular design, allowing laboratories to customize the system according to their specific needs and workflows. This flexibility not only supports sustained high throughput but also accommodates evolving laboratory demands. By automating key steps in the sample processing, CURECA™ promotes efficiency, reduces labor costs, and ultimately enhances patient care through faster and more reliable testing.

Dr. Jong-Yoon Chun, Seegene's founder and CEO, expressed his vision for the future of molecular diagnostics, stating, "Until now, there hasn’t been a system capable of fully automating pre-processing for all sample types, which has hindered true MDx automation. We aspire to establish a new global standard and innovate the future of molecular diagnostics."

He emphasized that CURECA™ embodies Seegene's commitment to creating a "world free from diseases," a philosophy integral to the company’s operations and initiatives.

Beyond PCR: Expanding Horizons

Although primarily focused on PCR testing, CURECA™ and its underlying technologies offer potential applications across various laboratory disciplines including hematology, biochemistry, and immunodiagnostics. This adaptability not only validates its use within clinical laboratory workflows but also illustrates the potential for groundbreaking advances across the diagnostics landscape.

At ESCMID Global 2025, the company also highlighted its commitment to advancing molecular diagnostics through its ongoing initiatives, including discussions on antimicrobial resistance and the evolving role of diagnostics in a post-COVID era. With innovative analysis methods designed for rapid and informed treatment decisions, the conference showcased Seegene’s prowess in pushing the boundaries of current capabilities.

A Bright Future for Seegene

With over 20 years of experience in research and development, manufacturing, and business related to syndromic PCR testing, Seegene’s initiative aims to enhance global health. The company gained recognition after supplying over 340 million COVID-19 tests to more than 100 countries, proving its robustness in crisis management through technological advancement.

As the world moves towards a more interconnected approach to healthcare, Seegene’s CURECA™ stands as a beacon of innovation, striving towards a future where advanced molecular diagnostics are more accessible and integrated into everyday healthcare systems. CURECA™ is not just a product; it represents a movement towards comprehensive, automated, and efficient solutions in the fight against infectious diseases and beyond.

For more information about Seegene and their commitment to revolutionizing molecular diagnostics, visit Seegene’s website or follow their progress on LinkedIn.